Immune response to cancer and its regulation in regional lymph nodes

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 550-554

  Zheng, Rongxiu ^a   Shu, Suyu ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Providence Cancer Center   (United States)

Author keywords

DC tumor electrofusion hybrids; immune suppression; lymph node(s); therapeutic effector T cells

Indexed keywords

ARTICLE; CANCER GROWTH; DENDRITIC CELL; FIBROSARCOMA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; HYBRID CELLS; IMMUNOSUPPRESSION; LYMPH NODES; MICE; NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 79953870552     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21692     Document Type: Article

References (28)

1. Wilson NS, Villadangos JA,: Regulation of antigen presentation and cross-presentation in the dendritic cell network: Facts, hypothesis, and immunological implications. Adv Immunol 2005; 86: 241-305. (Pubitemid 40215695)
2. Steinman RM, Hemmi H,: Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58. (Pubitemid 47413194)
3. Villadangos JA, Schnorrer P,: Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007; 7: 543-555. (Pubitemid 46987783)
4. Fields RC, Shimizu K, Mule JJ,: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487. (Pubitemid 28506257)
5. Zitvogel L, Mayordomo JI, Tjandrawan T, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97. (Pubitemid 26028748)
6. Boczkowski D, Nair SK, Snyder D, et al.: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472. (Pubitemid 26324100)
7. Gong J, Chen D, Kashiwaba M, et al.: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6279-6283. (Pubitemid 28249003)
8. Gong J, Nikrui N, Chen D, et al.: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165: 1705-1711. (Pubitemid 30604610)
9. Gong J, Avigan D, Chen D, et al.: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 2715-2718. (Pubitemid 30159237)
10. Avigan D, Vasir B, Gong J, et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699-4708. (Pubitemid 38955520)
11. Hayashi T, Tanaka H, Tanaka J, et al.: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002; 104: 14-20. (Pubitemid 34856504)
12. Parkhurst MR, DePan C, Riley JP, et al.: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003; 170: 5317-5325. (Pubitemid 36554767)
13. Neil GA, Zimmermann U,: Electrofusion. Methods Enzymol 1993; 220: 174-196. (Pubitemid 23260711)
14. White KL,: Electrofusion of mammalian cells. Methods Mol Biol 1995; 48: 283-293.
15. Kuriyama H, Shimizu K, Lee W, et al.: Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 2004; 116: 169-178, discussion 179-186.
16. Kjaergaard J, Shimizu K, Shu S,: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225: 65-74. (Pubitemid 38091551)
17. Shimizu K, Kuriyama H, Kjaergaard J, et al.: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 2004; 27: 265-272. (Pubitemid 38833322)
18. Kjaergaard J, Wang LX, Kuriyama H, et al.: Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 2005; 103: 156-164. (Pubitemid 43193947)
19. Tamai H, Watanabe S, Zheng R, et al.: Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 2008; 127: 66-77.
20. Hanna MG, Jr., Bucana CD, Pollack VA,: Immunological stimulation in situ: The acute and chronic inflammatory responses in the induction of tumor immunity. Contemp Top Immunobiol 1980; 10: 267-296.
21. Cahalan MD, Parker I,: Imaging the choreography of lymphocyte trafficking and the immune response. Curr Opin Immunol 2006; 18: 476-482. (Pubitemid 43947583)
22. Yoshizawa H, Chang AE, Shu S,: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147: 729-737.
23. Yoshizawa H, Chang AE, Shu SY,: Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res 1992; 52: 1129-1136.
24. Zou W,: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
25. Rabinovich GA, Gabrilovich D, Sotomayor EM,: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296. (Pubitemid 46697910)
26. Sinha P, Clements VK, Bunt SK, et al.: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
27. Watanabe S, Deguchi K, Zheng R, et al.: Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008; 181: 3291-3300.
28. Poehlein CH, Haley DP, Walker EB, et al.: Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol 2009; 39: 3121-3133.